Ocular Therapeutix (NASDAQ:OCUL – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Saturday, Zacks.com reports. According to Zacks, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel […]
Ocular Therapeutix (NASDAQ:OCUL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Zacks.com reports. According to Zacks, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its […]
Ocular Therapeutix (NASDAQ:OCUL – Get Rating) had its price target dropped by research analysts at Piper Sandler from $16.00 to $10.00 in a report released on Friday, The Fly reports. Piper Sandler’s target price would indicate a potential upside of 213.48% from the company’s previous close. Other equities analysts have also issued research reports about […]
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Rating) has been assigned a consensus rating of “Buy” from the six research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, one has issued a buy recommendation and one has issued […]
Ocular Therapeutix (NASDAQ:OCUL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using […]